Sourasky Medical Center (Ichilov)
| イスラエル | トルコ | オーストリア | |
| 胃癌手術 | から $28,500 | から $22,320 | から $30,000 |
| 胃切除術 | から $22,500 | から $16,470 | から $22,000 |
| 乳癌化学療法 | から $22,500 | から $1,200 | から $15,000 |
| 大腸癌に対する放射線療法 | - | から $7,000 | から $12,000 |
ペレス・シャロン医師は、スーラスキー医療センター（イチロフ）にて胃癌外科を専門とし、HIPEC（腹腔内温熱化学療法）や免疫療法などの先進的な治療に精通しています。
メリムスキー教授は、スーラスキー医療センターの軟部組織・骨腫瘍科を率い、胃癌の専門的な診療において数十年の経験を有しています。
この医師は、消化管腫瘍の治療において30年以上の経験を持つ、著名な消化器専門医です。GIがんの予防、早期診断、および治療を専門としており、Sourasky Medical CenterのCancer Prevention Centerを率いています。
ヘブライ大学で一般医学の学位を取得し、テルアビブ大学で消化器学の専門を修了したこの医師は、NewYork-Presbyterian Centerで研究を行いました。この医師は300以上の論文を発表しており、American Association for Cancer ResearchやEuropean Society of Digestive Oncologyを含む、いくつかの著名な組織のメンバーです。
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Stage 2 stomach cancer treatment in Israel follows a multidisciplinary approach focusing on complete tumor removal and preventing recurrence. Primary protocols combine neoadjuvant chemotherapy, radical resection with D2 lymph node dissection, and adjuvant systemic therapies. Precision medicine guides the use of targeted drugs based on molecular profiling.
Bookimed Expert Insight: While most centers perform gastrectomies, high-volume facilities like Sheba Medical Center and Sourasky Medical Center report superior outcomes due to specialized D2 lymphadenectomy expertise. These centers perform over 34,000 to 45,000 surgeries annually. This volume is critical because D2 dissection is technically demanding. Choosing a facility with Nobel Prize-winning specialists or Forbes-listed physicians often ensures access to advanced intraoperative pathology, like the frozen express test, which confirms cancer-free margins during the procedure.
Patient Consensus: Patients emphasize the need for molecular testing before starting chemotherapy to ensure the drugs match the tumor type. Many note that preparing for major nutritional shifts and lifelong vitamin B12 supplementation is essential after a gastrectomy.
Surgery is the primary curative treatment for stage 2 gastric cancer but is rarely performed alone. Israeli protocols often prioritize perioperative chemotherapy to shrink tumors before resection. Surgery may be bypassed if the tumor involves vital structures or if the patient is medically frail.
Bookimed Expert Insight: Israeli centers like Sheba and Sourasky lead in robotic surgery, which is crucial for complex D2 node dissections. Dr. Yuri Goldes at Sheba was among the first to perform robotic stomach resections. This technology helps surgeons achieve cleaner margins while typically reducing blood loss compared to traditional open surgery.
Patient Consensus: Patients emphasize that adding chemotherapy before surgery significantly improves outcomes. Many note that managing small, frequent meals and B12 shots becomes a necessary but manageable life adjustment after recovery.
Advanced gastric cancer surgery in Israel utilizes the da Vinci robotic system for precise gastrectomies. Surgeons perform laparoscopic HIPEC and endoscopic mucosal resections to ensure organ preservation. These minimally invasive techniques involve small incisions. This results in faster recovery times and higher oncological success rates.
Bookimed Expert Insight: Israeli surgical departments demonstrate a unique volume-to-specialization ratio seen at centers like Sheba Medical Center. Dr. Yuri Goldes and Dr. Almog Ben Yaacov have performed over 200 HIPEC procedures. This specific experience is rare globally. It allows for the application of HIPEC even in select stage 2 cases with high peritoneal risk.
Patient Consensus: Patients note that robotic-assisted recovery is significantly faster than traditional surgery. Many emphasize that laparoscopic D2 lymphadenectomy provides peace of mind due to the high lymph node yield.
Immunotherapy is frequently used for Stage 2 stomach cancer to prevent recurrence, especially for patients with MSI-high biomarkers. Israeli oncology centers typically reserve HIPEC and PIPAC for metastatic disease. These specialized therapies are rarely standard for localized Stage 2 tumors unless part of specific clinical trials.
Bookimed Expert Insight: Israeli specialists like Dr. Almog Ben Yaacov have performed over 200 HIPEC procedures, reflecting deep expertise in specialized chemotherapy. While HIPEC is standard for advanced stages, the high volume of operations in centers like Sheba and Sourasky means patients access highly refined protocols. Data shows top Israeli centers handle over 1 million patients annually, offering a concentration of experience that helps doctors determine when aggressive innovative therapies might benefit high-risk Stage 2 cases.
Patient Consensus: Patients emphasize the importance of requesting MSI-high and PD-L1 testing early to unlock immunotherapy options. Those with Stage 2 cancer often note that while standard surgery and chemotherapy are common, seeking second opinions at trial-heavy centers is vital for exploring advanced safety gaps.
Sheba and Sourasky (Ichilov) lead gastric cancer treatment in Israel. These JCI-accredited centers specialize in robotic gastrectomies and HIPEC. They integrate precision medicine with genetic profiling for stage 2 cases. Multidisciplinary teams achieve high survival rates through minimally invasive surgery and targeted biological therapies.
Bookimed Expert Insight: While many seek private care for speed, Sheba Medical Center serves over 2 million patients annually. This volume is critical for gastric cancer. High-volume centers often show better outcomes for complex resections. Dr. Yuri Goldes, a Forbes-recognized specialist there, even pioneered the country's first robotic resections. This institutional experience often outweighs the shorter wait times at smaller private clinics.
Patient Consensus: Patients note that major public hospitals dominate complex stage 2 cases. They often provide faster access to experimental trials than centers in Europe. Many emphasize that while private clinics offer quicker scheduling, the multidisciplinary teams at Hadassah and Sheba remain the gold standard for integrated oncology care.
International patients typically stay in Israel for 3 to 6 months for continuous Stage 2 stomach cancer treatment. This duration covers advanced diagnostics, surgical resection, and perioperative chemotherapy. Most patients spend 4 to 8 weeks for the surgical phase alone to ensure safe recovery.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center report a 90% average success rate. While the full protocol lasts months, our data shows many patients choose a split-trip model. They stay 4 to 6 weeks for surgery and then return home for chemotherapy. This approach works if local oncologists can coordinate with Israeli professors like Dr. Alexander Beny or Dr. Ido Wolf.
Patient Consensus: Patients note it is vital to stay 6 to 8 weeks for the first phase. They emphasize not flying home until cleared to avoid risks like blood clots or surgical issues.